2. Search Result
Search Result
Results for "

domains

" in MedChemExpress (MCE) Product Catalog:

756

Inhibitors & Agonists

5

Screening Libraries

3

Fluorescent Dye

5

Biochemical Assay Reagents

167

Peptides

68

Inhibitory Antibodies

52

Natural
Products

40

Recombinant Proteins

18

Isotope-Labeled Compounds

3

Antibodies

2

Click Chemistry

1

Oligonucleotides

Cat. No. Product Name Target Research Area
  • HY-P0306
    Fibronectin Adhesion-promoting Peptide

    Heparin Binding Peptide

    		 Peptides Cardiovascular Disease
    Fibronectin Adhesion-promoting Peptide (Heparin Binding Peptide) is one of the heparin-binding amino acid sequences found in the carboxy-terminal heparin-binding domain of fibronectin. It promotes assembly of mesenchymal stem cell (MSC) spheroids into larger aggregates. Fibronectin Adhesion-promoting Peptide directly promotes the adhesion, spreading, and migration of endothelial cells by reacting with heparin binding domains of cells .
  • HY-P10108
    Hexokinase II VDAC binding domain peptide, cell-permeable

    Hxk2VBD peptide, cell-permeable

    		 Hexokinase Neurological Disease
    Hexokinase II VDAC binding domain peptide (Hxk2VBD peptide) is a cell-permeable hexokinase II VDAC binding domain. Hexokinase II VDAC binding domain peptide inhibits mitochondrial localization of hexokinase 2 (HXK2). Hexokinase II VDAC binding domain peptide inhibits neurotrophic factor-directed axon outgrowth .
  • HY-P10366
    WEYIPNV

    		Peptides Infection
    WEYIPNV is a ligand for SurA, specifically binding to the P1 domain of SurA (Kd: 1-14 μM). The binding of WEYIPNV promotes the release of the P1 domain from the core domain .
  • HY-P4525
    Ala-Ala-Ala-Ala

    		Peptides Others
    Ala-Ala-Ala-Ala is a poly-L-alanine (PLA) sequences. PLA is a kind of key element of the crystalline domains of spider dragline and wild silkworm silks .
  • HY-P10566
    BCOR(498-514), biotinylated

    		BCL6 Cancer
    BCOR(498-514), biotinylated is the minimal BCL6 binding domain with an KD value of 1.32 µM. BCOR(498-514), biotinylated blocks BCL6-mediated transcriptional repression and kills lymphoma cells .
  • HY-P10152
    INF7

    		Peptides Infection
    INF7 is a derivative of the N-terminal domain of the HA2 protein that can be used to enhance the endosomal escape of polyplexes or liposome-encapsulated proteins .
  • HY-P0306A
    Fibronectin Adhesion-promoting Peptide TFA

    Heparin Binding Peptide TFA

    		 Peptides Cardiovascular Disease
    Fibronectin Adhesion-promoting Peptide (Heparin Binding Peptide) is one of the heparin-binding amino acid sequences found in the carboxy-terminal heparin-binding domain of fibronectin. It promotes assembly of mesenchymal stem cell (MSC) spheroids into larger aggregates. Fibronectin Adhesion-promoting Peptide directly promotes the adhesion, spreading, and migration of endothelial cells by reacting with heparin binding domains of cells .
  • HY-P4101
    Cys(Npys)-TAT (47-57)

    		HIV Infection
    Cys(Npys)-TAT (47-57) is a peptide fragment of TAT peptide and it is able to interact with plasmid DNA electrostatically. Cys(Npys)-TAT (47-57) is corresponding to the transduction domain of TAT with an activated cysteine residue C. TAT is a small nuclear transcriptional activator protein encoded by HIV-1 .
  • HY-P10105
    TCL1(10-24)

    		Akt Apoptosis Cancer
    TCL1(10-24) is a encompassing the betaA strand of human TCL1. TCL1(10-24) is a Akt inhibitor. TCL1(10-24) interacts with the Akt PH domain prevented phosphoinositide binding and hence inhibits membrane translocation and activation of Akt. TCL1(10-24) inhibits cellular proliferation and anti-apoptosis. TCL1(10-24) has tumor growth in vivo .
  • HY-P4110
    TAT-NSF222 Fusion Peptide

    		Peptides Metabolic Disease Inflammation/Immunology
    TAT-NSF222 Fusion Peptide is a fusion polypeptide with two domains, a TAT domain, which enters cells through macropinocytosis, and an NSF domain that inhibits N-ethylmaleimide-sensitive factor (NSF). TAT-NSF222 Fusion Peptide is an exocytosis inhibitor .
  • HY-P10521
    Apolipoprotein KV domain (67-77)

    		VEGFR Cancer
    Apolipoprotein KV domain (67-77) is an 11-amino acid peptide identified from the KV domain of human apolipoprotein a (ApoA) with antiangiogenic and antitumor activities. Apolipoprotein KV domain (67-77) targets the angiogenic c-Src/ERK pathway by blocking activation signals received from vascular endothelial growth factor (VEGF). Apolipoprotein KV domain (67-77) can be used in cancer research .
  • HY-P1195
    PDZ1 Domain inhibitor peptide

    		iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
  • HY-P1195A
    PDZ1 Domain inhibitor peptide TFA

    		iGluR Neurological Disease
    PDZ1 Domain inhibitor peptide TFA, a cyclic peptide, incorporates a β-Ala lactam side chain linker and targets the PDZ1 domains of the postsynaptic density protein 95 (PSD-95). PDZ1 Domain inhibitor peptide TFA disrupts the GluR6/PSD-95 interaction and is very efficient in competing against the C terminus of GluR6 for the PDZ1 domain .
  • HY-P1900
    SEB Domain (152-161)
    1 Publications Verification

    		 Peptides Infection
    SEB Domain (152-161) is Staphylococcal Enterotoxin B domain amino acid residue 152-161. Staphylococcal enterotoxin B (SEB) is a toxin produced by Staphylococcus aureus. SEB Domain (152-161) is highly conserved and can inhibit transcytosis of multiple staphylococcal enterotoxins, SEA, SEE, and TSST-1 .
  • HY-P1900A
    SEB Domain (152-161) (TFA)
    1 Publications Verification

    		 Peptides Infection
    SEB Domain (152-161) TFA is Staphylococcal Enterotoxin B domain amino acid residue 152-161. Staphylococcal enterotoxin B (SEB) is a toxin produced by Staphylococcus aureus. SEB Domain (152-161) TFA is highly conserved and can inhibit transcytosis of multiple staphylococcal enterotoxins, SEA, SEE, and TSST-1 .
  • HY-P4998
    Chemotactic Domain of Elastin

    		Biochemical Assay Reagents Cancer
    Chemotactic Domain of Elastin is an elastin-derived peptide with chemotactic effects on certain tumor cells, such as M27 tumor cells. Chemotactic Domain of Elastin can be used in cancer research .
  • HY-P1985A
    Notch 1 TFA

    		Notch Cardiovascular Disease Cancer
    Notch 1 TFA (Notch homolog 1, translocation-associated) can encode a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types .
  • HY-P5324
    Bad BH3 (mouse)

    		Bcl-2 Family Others
    Bad BH3 (mouse) is a biological active peptide. (This is a bcl-2 binding peptide. This peptide is derived from the BH3 domain (a death domain) of Bad, amino acid residues 140 to 165.)
  • HY-P3279
    EPQpYEEIPIYL
    1 Publications Verification

    		 Src Cancer
    EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains .
  • HY-P2516
    Tau Peptide (275-305) (Repeat 2 domain)

    		Tau Protein Neurological Disease
    Tau Peptide (275-305) (Repeat 2 domain) is the Alzheimer's tau fragment R2, corresponding to the second repeat unit of the microtubule-binding domain, which is believed to be pivotal to the biochemical properties of full tau protein .
  • HY-P10331
    KSL 128114

    		Peptides Cancer
    KSL 128114, a peptide inhibitor of syntenin, binds the PDZ1 domain of syntenin with nanomolar affinity. KSL 128114 is resistant toward degradation in human plasma and mouse hepatic microsomes and displays a global PDZ domain selectivity for syntenin .
  • HY-P4924
    Tau Peptide (244-274) (Repeat 1 Domain)

    		Tau Protein Neurological Disease
    Tau Peptide (244-274) (Repeat 1 Domain) is aTau fragment.
  • HY-P4927
    Tau Peptide (245-274) (Repeat 1 Domain)

    		Tau Protein Neurological Disease
    Tau Peptide (245-274) (Repeat 1 Domain) is aTau fragment.
  • HY-P4966
    Tau Peptide (306-336) (Repeat 3 Domain)

    		Tau Protein Neurological Disease
    Tau Peptide (306-336) (Repeat 3 Domain) is aTau fragment.
  • HY-P10543
    SMRT peptide

    		BCL6 Cancer
    SMRT peptide is one of the co-repressors of BCL6 BTB domain interaction. SMRT peptide binds to the BTB domain of BCL6 and enhances the transcriptional repression function of BCL6. SMRT peptide can be used to study protein-protein interactions .
  • HY-P5341
    Bik BH3

    		Bcl-2 Family Others
    Bik BH3 is a biological active peptide. (BH3 domain of BIK)
  • HY-P5342
    Hrk BH3

    		Bcl-2 Family Others
    Hrk BH3 is a biological active peptide. (BH3 domain of Hrk)
  • HY-P3787
    Ac-Asp-Tyr(PO3H2)-Val-Pro-Met-Leu-NH2

    		Peptides Metabolic Disease
    Ac-Asp-Tyr(PO3H2)-Val-Pro-Met-Leu-NH2 is the SH2 domain ligand. SH2 domains participate in protein tyrosine kinase (PTK)-mediated cellular signal .
  • HY-P5328
    Noxa A BH3

    		NADPH Oxidase Others
    Noxa A BH3 is a biological active peptide. (BH3 domain of Noxa protein)
  • HY-P4076
    MPG peptides, Pβ

    		Peptides Cancer
    MPG peptides, Pβ is a primary amphiphilic peptide consisting of three domains .
  • HY-P1816
    Fibronectin CS1 Peptide

    		Integrin Cancer
    The connecting segment 1 (CS-1) is a cell attachment domain located in the type III homology connecting segment (IIICS) of fibronectin. Fibronectin CS1 Peptide lacks the Arg-Gly-Asp-containing domain, actively inhibits tumor metastases in spontaneous and experimental metastasis models .
  • HY-P5329
    r8-Gly-Noxa A BH3

    		NADPH Oxidase Others
    r8-Gly-Noxa A BH3 is a biological active peptide. (This cell permeable peptide is derived from the BH3 domain (a death domain) of Noxa A, amino acid residues 17 to 36. Eight D-Arginine residues and a Glycine linker residue are added to the amino terminal of the peptide.)
  • HY-P5330
    Noxa B BH3

    		NADPH Oxidase Others
    Noxa B BH3 is a biological active peptide. (BH3 domain of Noxa protein)
  • HY-P4972
    Tau Peptide (45-73) (Exon 2/Insert 1 Domain)

    		Tau Protein Neurological Disease
    Tau Peptide (45-73) (Exon 2/Insert 1 Domain) is aTau fragment.
  • HY-P4977
    Tau Peptide (74-102) (Exon 3/Insert 2 Domain)

    		Tau Protein Neurological Disease
    Tau Peptide (74-102) (Exon 3/Insert 2 Domain) is aTau fragment.
  • HY-P5346
    Smac-based peptide

    		Peptides Others
    Smac-based peptide is a biological active peptide. (peptide from SMAC binding to BIR3 domain)
  • HY-P3590
    PQDVKFP

    		HCV Others
    PQDVKFP is a synthetic peptide, recognizing antigenic domains within the hepatitis C virus (HCV) core protein .
  • HY-P0300
    Bak BH3

    		Bcl-2 Family Cancer
    Bak BH3 is derived from the BH3 domain of Bak, can antagonize the function of Bcl-xL in cells.
  • HY-P10579
    123B9

    		Ephrin Receptor Cancer
    123B9, a tumor-homing agent, is a potent and selective EphA2 agonist with a Kd value of 4.0 μM. 123B9 selectively targets the EphA2 tyrosine kinase receptor ligand-binding domain. 123B9 does not appreciably inhibit the ligand binding domains of the most closely related EphA3 and EphA4 receptors .
  • HY-P10416
    Q14

    Q14 peptide

    		 Deubiquitinase Mitophagy Others Neurological Disease
    Q14 is a polypeptide derived from the USP30 (ubiquitin specific peptidase 30) transmembrane (TM) domain with the ability to inhibit the deubiquitination activity of USP30 (IC50=57.2 nM). Q14 reduces USP30 activity by inhibiting the interaction between the USP30 transmembrane domain and its catalytic domain. Q14 peptide contains the LC3 interaction region (LIR) motif, which enables it to bind to the LC3 and accelerate the formation of autophagosomes, thereby promoting mitophagy. Q14 can be used in the study of neurodegenerative diseases as well as mitochondrial quality control and cell metabolism .
  • HY-P1377
    Caffeic acid-pYEEIE

    		Src Inflammation/Immunology
    Caffeic acid-pYEEIE, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain .
  • HY-P1377A
    Caffeic acid-pYEEIE TFA

    		Src Inflammation/Immunology
    Caffeic acid-pYEEIE TFA, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain .
  • HY-P1562
    PUMA BH3

    		Bcl-2 Family Cancer
    PUMA BH3 is a p53 upregulated modulator of apoptosis (PUMA) BH3 domain peptide, acts as a direct activator of Bak, with a Kd of 26 nM.
  • HY-P5807
    Cn2 toxin

    β-Mammal toxin Cn2

    		 Peptides Neurological Disease
    Cn2 toxin is aβ- toxoins. Cn2 toxin can bind to the voltage sensing domain of voltage gated sodium channels (Nav) .
  • HY-P10550
    VGB4

    		VEGFR Cancer
    VGB4 is a VEGF-A and VEGF-B antagonist peptide that duplicates two binding domains of VEGF-B (loop 1 and loop3) and are linked together by the receptor-binding domain of VEGF-A (loop3). VGB4 has significant anti-angiogenic and anti-tumor activities and can regulate tumor growth and metastasis through multiple mechanisms. VGB4 could be used in anti-tumor research .
  • HY-P5424
    RyR1(3614-3643)

    		Peptides Others
    RyR1(3614-3643) is a biological active peptide. (the absolutely conserved peptide corresponding to the CaM-binding domain of RyR1 in all vertebrates)
  • HY-P5454
    RS Domain derived peptide

    		Peptides Others
    RS Domain derived peptide is a biological active peptide. (This peptide is a substrate for Clk/Sty and is phosphorylated by Clk/Sty protein kinase (Km=102 microM).)
  • HY-P1562A
    PUMA BH3 TFA

    		Bcl-2 Family Cancer
    PUMA BH3 TFA is a p53 upregulated modulator of apoptosis (PUMA) BH3 domain peptide, acts as a direct activator of Bak, with a Kd of 26 nM .
  • HY-P5421
    Caloxin 1B1

    		Peptides Others
    Caloxin 1B1 is a biological active peptide. (Caloxin 1b1 is obtained by screening for binding to extracellular domain 1 of PMCA4, which inhibited PMCA extracellularly, selectively, and had a higher affinity for PMCA4 than PMCA1. Because caloxin 1b1 had been selected to bind to an extracellular domain of PMCA, it could be added directly to cells and tissues to examine its effects on smooth muscle and endothelium.)
  • HY-P10495
    GPR110 peptide agonist P12

    		Peptides Others Cancer
    GPR110 peptide agonist P12 is a peptide that acts as a GPR110 agonist. GPR110 peptide agonist P12 can significantly enhance the initial rate of GPR110 stimulated G protein GTPγS binding. GPR110 peptide agonist P12 mimics the action of natural ligands, causing the extracellular domain (ECD) of the GPR110 to dissociate from the seven transmembrane domains (7TM), exposing the β-strand-13/stalk region at the N-terminus of the 7TM domain, which acts as an agonist to activate G protein signaling. GPR110 peptide agonist P12 can be used in the study of developmental disorders and cancers related to GPR110 .

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: